Neuraxis, Inc. NRXS
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $13.00 (+70.4% upside)
Key Stats
- Today's Range
- $7.25 – $8.06
- 50-Day Range
- $5.31 – $8.06
- 52-Week Range
- $2.21 – $9.33
- Volume
- 517K shs
- Average Volume
- 130K shs
- Market Cap
- $87.15 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 12.94
- Price / Sales
- 16.39
Short Interest
- Short Interest
- 0.02%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $5.32 million
- Net Income
- $-7,678,631
- Net Margin
- -144.44%
- Return on Equity
- -114.01%
- Debt-to-Equity
- —
About Neuraxis, Inc.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Related Stocks
Compare head-to-head: NRXS vs MDT·NRXS vs AXGN·NRXS vs BLFS·NRXS vs CNMD
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.